Interferon-alfa-based treatment of chronic myeloid leukemia and implications of signal transduction inhibition (Q34349068)

1 August 2017

1 reference

title

Interferon-alfa-based treatment of chronic myeloid leukemia and implications of signal transduction inhibition (English)

1 reference

1 August 2017

chronic myeloid leukemia

0 references

1 reference

Talpaz M

1

1 reference

1 August 2017

1 July 2001

1 reference

1 August 2017

Seminars in Hematology

1 reference

1 August 2017

38

1 reference

1 August 2017

3 Suppl 8

1 reference

1 August 2017

22-27

1 reference

Interferons and their actions

1 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990114-3

7 January 2021

Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon-alpha therapy. The Leukemia Service

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990114-3

7 January 2021

Hematologic remission and cytogenetic improvement induced by recombinant human interferon alpha A in chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990114-3

7 January 2021

Persistence of dormant leukemic progenitors during interferon-induced remission in chronic myelogenous leukemia. Analysis by polymerase chain reaction of individual colonies

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990114-3

7 January 2021

Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990114-3

7 January 2021

Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. French Chronic Myeloid Leukemia Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990114-3

7 January 2021

Treatment of Philadelphia chromosome-positive early chronic phase chronic myelogenous leukemia with daily doses of interferon alpha and low-dose cytarabine

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990114-3

7 January 2021

Chronic myelogenous leukemia in nonlymphoid blastic phase: analysis of the results of first salvage therapy with three different treatment approaches for 162 patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990114-3

7 January 2021

Clinical course and therapy of chronic myelogenous leukemia with interferon-alpha and chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990114-3

7 January 2021

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990114-3

7 January 2021

10.1016/S0037-1963(01)90114-3

Identifiers

DOI

1 reference

1 August 2017

1 reference

PubMed ID

11526598